Remarkably, we demonstrated that EP300 inhibition reduced fibrotic hallmarks in vitro using primary fibroblasts from Ctrl and IPF patients, in vivo using the bleomycin mouse model, and ex vivo using PCLS. Here, EP300 is linked to idiopathic pulmonary fibrosis.